These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 21688702)
1. Proposed EU-India free trade agreement could impede manufacture of generic HIV drugs. Chu SK HIV AIDS Policy Law Rev; 2011 Apr; 15(2):22-3. PubMed ID: 21688702 [TBL] [Abstract][Full Text] [Related]
2. Indian generic drug production. Benefits of EU-India free trade agreement. Ager B BMJ; 2011 Apr; 342():d2439. PubMed ID: 21502277 [No Abstract] [Full Text] [Related]
3. Impact of the trade-related aspects of intellectual property rights (TRIPS) agreement on India as a supplier of generic antiretrovirals. Babovic S; Wasan KM J Pharm Sci; 2011 Mar; 100(3):816-21. PubMed ID: 20740678 [TBL] [Abstract][Full Text] [Related]
4. Charities lobby EU over access to generic drugs. Gulland A BMJ; 2012 Feb; 344():e1066. PubMed ID: 22331320 [No Abstract] [Full Text] [Related]
5. India cancels trade talks after Europe bans 700 generic drugs. Krishnan V BMJ; 2015 Aug; 351():h4387. PubMed ID: 26268248 [No Abstract] [Full Text] [Related]
6. Canada ordered to implement WTO ruling against "stockpiling" of generic drugs. Elliott R Can HIV AIDS Policy Law Rev; 2000; 5(4):27. PubMed ID: 11833161 [TBL] [Abstract][Full Text] [Related]
8. International trade and Canadian patent law. Elliott R Can HIV AIDS Policy Law Rev; 2001; 6(1-2):47-53. PubMed ID: 11837027 [No Abstract] [Full Text] [Related]
9. The production of generic drugs in India. Love J BMJ; 2011 Mar; 342():d1694. PubMed ID: 21427048 [No Abstract] [Full Text] [Related]
10. Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity. Morag-Sela T; Cohn I; Kowalski TJ; Jarecki-Black J; Clyde-Watson Z Nat Biotechnol; 2004 Dec; 22(12):1591-2. PubMed ID: 15583670 [No Abstract] [Full Text] [Related]
11. Mixed WTO ruling on generic drug development. Elliott R Can HIV AIDS Policy Law Newsl; 2000; 5(2-3):38-42, 40-4. PubMed ID: 11833195 [TBL] [Abstract][Full Text] [Related]
12. Drug marketing exclusivity under United States and European Union law. Junod V Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347 [No Abstract] [Full Text] [Related]
13. Canada to change patent law to allow export of cheap drugs. Kondro W Lancet; 2003 Oct; 362(9392):1290. PubMed ID: 14577437 [No Abstract] [Full Text] [Related]
14. The World Health Organization's prequalification program and its potential effect on data exclusivity laws. Childs DW Food Drug Law J; 2005; 60(1):79-97. PubMed ID: 15940855 [No Abstract] [Full Text] [Related]
15. World Trade Organization still threatens supply of affordable AIDS drugs. Hagmann M Bull World Health Organ; 2002; 80(9):762-3. PubMed ID: 12378300 [No Abstract] [Full Text] [Related]
16. TRIPS AGREEMENT ARTICLE 31(B): THE NEED FOR REVISION. Effingham AM Seton Hall Law Rev; 2016; 46(3):883-909. PubMed ID: 27066613 [No Abstract] [Full Text] [Related]
17. Restrictions on generic drugs "infringe the right to health". Moszynski P BMJ; 2010 Dec; 341():c7246. PubMed ID: 21163838 [No Abstract] [Full Text] [Related]
18. Essential AIDS medications in India. Thomas J Issues Med Ethics; 2000; 8(2):62. PubMed ID: 16323350 [No Abstract] [Full Text] [Related]
19. CAFTA will harm HIV care, according to critics. Final agreement helps drug companies, they say. AIDS Alert; 2004 Feb; 19(2):17-8. PubMed ID: 15011625 [TBL] [Abstract][Full Text] [Related]